New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
08:40 EDTALXNAlexion gets positive CHMP opinion on extended indication for eculizumab
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Soliris. The marketing authorization holder for this medicinal product is Alexion Europe SAS. Soliris is currently authorized for the treatment of paroxysmal nocturnal haemoglobinuria in adults only and atypical haemolytic uremic syndrome in adults and children. The CHMPís opinion now recommends that the PNH indication be extended to include children, the EMA announced.
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
07:44 EDTALXNAlexion valuation looking increasingly compelling, says Stifel
Subscribe for More Information
July 24, 2014
11:53 EDTALXNAlexion price target raised to $214 from $196 at Piper Jaffray
Subscribe for More Information
06:43 EDTALXNAlexion raises 2014 adjusted EPS view to $4.95-$5.05 from $4.75-$4.85
Subscribe for More Information
06:41 EDTALXNAlexion reports Q2 adjusted EPS $1.12, consensus $1.07
Subscribe for More Information
06:17 EDTALXNAlexion's hypophosphatasia candidate MAA accepted by European Medicines Agency
Subscribe for More Information
July 22, 2014
11:48 EDTALXNStocks with call strike movement; EXPE ALXN
Subscribe for More Information
July 16, 2014
10:01 EDTALXNPegasystems appoints Warner Chief Compliance Officer
Subscribe for More Information
08:01 EDTALXNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use